Recall of Bextra

Despite this evidence of Bextra stroke and heart attack risks, Pfizer made no indication of any plans to recall their defective drug or strengthen warning labels. In response to Bextra stroke and heart attack risks, the FDA urged doctors to limit their use of Bextra and look to alternatives for prescription pain relief. The FDA and other regulatory agencies ordered a review of all Bextra clinical trials to further evaluate Bextra stroke and heart attack risks. After comprehensive investigation, the FDA determined that Bextra stroke, heart attack, and skin risks were too great to allow this drug to remain on the market.